Abstract: The present disclosure relates to a sweetener composition comprising a transfructosylated steviol glycoside, and a method for improving the sweetness of a steviol glycoside, comprising converting a steviol glycoside into a transfructosylated steviol glycoside.

Abstract: The present disclosure relates to a method for preparing a fermented soy product comprising: inoculating a Bacillus amyloliquefaciens CJ24-34 (KCCM12038P) strain into a soybean meal or a soy protein concentrate; and obtaining a fermented soybean meal or a fermented soy protein concentrate, which is fermented by culturing the Bacillus amyloliquefaciens strain, a fermented soy product prepared by the method, and an animal feed composition comprising the fermented product. The fermented soy product prepared by the method does not contain mucilage, shows an excellent antibacterial activity, and has a high content of low molecular weight peptides.

Abstract: The present disclosure relates to a method for preparing a transfructosylated steviol glycoside using Arthrobacter-derived microorganisms, a culture thereof, a supernatant of the culture, an extract of the culture, and a lysate of the microorganisms.

Abstract: Provided are a hexuronate C4-epimerase variant with improved activity in converting D-fructose by D-tagatose of hexuronate C4-epimerase and a method for production of D-tagatose using them.

Abstract: The present invention relates to a sweetening material composition and a method for preparing the same. Specifically, the present invention relates to a sweetening material composition including transglycosylation steviol glycosides and a method for preparing the same. The sweetening material composition of the present invention includes transglycosylated stevia and saccharides, and the saccharides include 5 to 90 parts by weight of an oligosaccharide having a degree of polymerization (DP) of 3 or more with respect to 100 parts by weight.

Abstract: Provided is a multifunctional connector. The multifunctional connector includes an auxiliary conduit which is branched from a main conduit and has a guide portion; and an operation member provided detachably from the auxiliary conduit, wherein the operation member includes an intubation portion inserted into the auxiliary conduit; sliding guide formed to move forward and backward while being guided by the guide portion; a fixing cap fixing the sliding guide so as not to be separated from the guide portion; and a first port through which a fluid is injected or discharged, thereby improving the efficiency of treatment, mitigating the fatigue of medical staffs, and reducing contamination of affected areas and a risk of damage to tissues around an endoscope.

Abstract: The present invention relates to a novel thermophilic and thermoresistant polyphosphate-dependent glucokinase having excellent stability, a composition comprising the same, and a method for producing glucose 6-phosphate using the same.

Abstract: The present application relates to a psicose-6-phosphate phosphatase, a microorganism comprising the same, and a method for producing psicose using the same.

Abstract: A system and method for analyzing a data store of de-identified patient data to generate one or more dynamic user interfaces usable to predict an expected response of a particular patient population or cohort when provided with a certain treatment. The automated analysis of patterns occurring in patient clinical, molecular, phenotypic, and response data, as facilitated by the various user interfaces, provides an efficient, intuitive way for clinicians to evaluate large data sets to aid in the potential discovery of insights of therapeutic significance.

Abstract: Provided are a fructose-4-epimerase variant having tagatose conversion activity, and a method of producing tagatose using the same.

Abstract: Provided are a novel fructose-C4-epimerase and a method of producing tagatose using the same.

Abstract: The present invention relates to a composition for preventing or treating a muscle disorder, which includes a Chrysanthemum extract or 3,5-dicaffeoylquinic acid as an active ingredient, and specifically, it may be used to reduce mRNA expression of atrogin-1 and MuRF1, which are main biomarkers involved in muscle protein degradation and increase mRNA expression of the mTOR protein, which is a main biomarker involved in muscle protein formation, and myogenin and MyoD, which are biomarkers related to muscle differentiation, thereby reducing muscle loss, and thus the Chrysanthemum extract or 3,5-dicaffeoylquinic acid can be used in prevention and treatment of a muscle disorder, or improvement in muscle function. In addition, the Chrysanthemum extract or 3,5-dicaffeoylquinic acid increases the activity of SIRT1 and PGC-1?, which are the main biomarkers involved in exercise performance, thereby excellently enhancing exercise performance.

Abstract: The present application relates to an allulose-containing composition for promoting excretion of vegetable lipids from the body and a food comprising the composition of the present application and vegetable lipids.

Abstract: Provided are a tagatose-bisphosphate aldolase variant having tagatose conversion activity, and a method of preparing tagatose using the same.

Abstract: Provided are a fructose-4-epimerase variant having tagatose conversion activity, and a method of preparing tagatose using the same.

Abstract: Provided are a composition for producing tagatose, comprising fructose-4-epimerase, and a method of producing tagatose using the same.

Abstract: The present application relates to a psicose-6-phosphate phosphatase comprising motif A and motif B, a composition for producing D-psicose comprising the enzyme, and a method for producing D-psicose using the enzyme.

Abstract: Provided are a novel D-psicose 3-epimerase and a method for preparing psicose using the same.

Abstract: The present invention relates to a composition for preventing or treating a muscle disorder, which includes a chrysanthemum extract or 3,5-dicaffeoylquinic acid as an active ingredient, and specifically, it may be used to reduce mRNA expression of atrogin-1 and MuRF1, which are main biomarkers involved in muscle protein degradation and increase mRNA expression of the mTOR protein, which is a main biomarker involved in muscle protein formation, and myogenin and MyoD, which are biomarkers related to muscle differentiation, thereby reducing muscle loss, and thus the chrysanthemum extract or 3,5-dicaffeoylquinic acid can be used in prevention and treatment of a muscle disorder, or improvement in muscle function. In addition, the chrysanthemum extract or 3,5-dicaffeoylquinic acid increases the activity of SIRT1 and PGC-1?, which are the main biomarkers involved in exercise performance, thereby excellently enhancing exercise performance.